Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices 5501

Drug Schedule this time. DEA has investigated DEPARTMENT OF JUSTICE Noramco, Inc., to ensure that the Hydromorphone (9150) ...... II company’s registration is consistent Drug Enforcement Administration Hydrocodone (9193) ...... II with the public interest. The (9300) ...... II investigation has included inspection Manufacturer of Controlled Oripavine (9330) ...... II Substances; Notice of Registration; Thebaine (9333) ...... II and testing of the company’s physical Opium extracts (9610) ...... II security systems, verification of the Cerilliant Corporation Opium fluid extract (9620) ...... II company’s compliance with state and Opium tincture (9630) ...... II local laws, and a review of the By Notice dated August 17, 2012, and Opium, powdered (9639) ...... II company’s background and history. published in the Federal Register on Opium, granulated (9640) ...... II Therefore, pursuant to 21 U.S.C. 823(a), August 29, 2012, 77 FR 52366, Cerilliant Oxymorphone (9652) ...... II Corporation, 811 Paloma Drive, Suite A, Noroxymorphone (9668) ...... II and in accordance with 21 CFR 1301.33, Tapentadol (9780) ...... II the above named company is granted Round Rock, Texas 78665–2402, made registration as a bulk manufacturer of application by renewal to the Drug The company plans to manufacture the basic classes of controlled Enforcement Administration (DEA) to the listed controlled substances in bulk substances listed. be registered as a bulk manufacturer of for distribution to its customers. the following basic classes of controlled No comments or objections have been Dated: January 15, 2013. substances: received. DEA has considered the Joseph T. Rannazzisi, factors in 21 U.S.C. 823(a) and Deputy Assistant Administrator, Office of determined that the registration of Diversion Control, Drug Enforcement Noramco, Inc., to manufacture the listed Administration. basic classes of controlled substances is [FR Doc. 2013–01600 Filed 1–24–13; 8:45 am] consistent with the public interest at BILLING CODE 4410–09–P

Drug Schedule

Cathinone (1235) ...... I Methcathinone (1237) ...... I 4-Methyl-N-methylcathinone (1248) ...... I N-Ethylamphetamine (1475) ...... I N,N-Dimethylamphetamine (1480) ...... I Fenethylline (1503) ...... I Aminorex (1585) ...... I 4-Methylaminorex (cis isomer) (1590) ...... I Gamma Hydroxybutyric Acid (2010) ...... I Methaqualone (2565) ...... I 1-Pentyl-3-(1-naphthoyl)indole (7118) ...... I 1-Butyl-3-(1-naphthoyl)indole (7173) ...... I 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole (7200) ...... I Alpha-ethyltryptamine (7249) ...... I 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol] (7297) ...... I 5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol] (7298) ...... I Lysergic acid diethylamide (7315) ...... I 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) ...... I Marihuana (7360) ...... I (7370) ...... I Parahexyl (7374) ...... I (7381) ...... I 3,4,5- (7390) ...... I 4-Bromo-2,5-dimethoxyamphetamine (7391) ...... I 4-Bromo-2,5-dimethoxyphenethylamine (7392) ...... I 4-Methyl-2,5-dimethoxyamphetamine (7395) ...... I 2,5-Dimethoxyamphetamine (7396) ...... I 2,5-Dimethoxy-4-ethylamphetamine (7399) ...... I 3,4-Methylenedioxyamphetamine (7400) ...... I 5-Methoxy-3,4-methylenedioxyamphetamine (7401) ...... I N-Hydroxy-3,4-methylendioxyamphetamine (7402) ...... I 3,4-Methylendioxy-N-ethylamphetamine (7404) ...... I 3,4-Methylenedioxymethamphetamine (7405) ...... I 4-Methoxyamphetamine (7411) ...... I 5-Methoxy-N-N-dimethyltryptamine (7431) ...... I Alpha-methyltryptamine (7432) ...... I Bufotenine (7433) ...... I (7434) ...... I Dimethyltryptamine (7435) ...... I (7437) ...... I Psilocyn (7438) ...... I 5-Methoxy-N,N- (7439) ...... I N-Ethyl-1-phenylcyclohexylamine (7455) ...... I 1-(1-Phenylcyclohexyl)pyrrolidine (7458) ...... I 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ...... I N- (7493) ...... I

VerDate Mar<15>2010 18:39 Jan 24, 2013 Jkt 229001 PO 00000 Frm 00095 Fmt 4703 Sfmt 4703 E:\FR\FM\25JAN1.SGM 25JAN1 mstockstill on DSK4VPTVN1PROD with 5502 Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices

Drug Schedule

Acetyldihydrocodeine (9051) ...... I Benzylmorphine (9052) ...... I Codeine-N-oxide (9053) ...... I Codeine methylbromide (9070) ...... I Dihydromorphine (9145) ...... I (9200) ...... I Hydromorphinol (9301) ...... I Methyldesorphine (9302) ...... I Methyldihydromorphine (9304) ...... I Morphine methylbromide (9305) ...... I Morphine methylsulfonate (9306) ...... I Morphine-N-oxide (9307) ...... I Normorphine (9313) ...... I Pholcodine (9314) ...... I Acetylmethadol (9601) ...... I Allylprodine (9602) ...... I Alphacetylmethadol except levo-alphacetylmethadol (9603) ...... I Alphameprodine (9604) ...... I Alphamethadol (9605) ...... I Betacetylmethadol (9607) ...... I Betameprodine (9608) ...... I Betamethadol (9609) ...... I Betaprodine (9611) ...... I Dipipanone (9622) ...... I Hydroxypethidine (9627) ...... I Noracymethadol (9633) ...... I Norlevorphanol (9634) ...... I Normethadone (9635) ...... I Trimeperidine (9646) ...... I Phenomorphan (9647) ...... I 1-Methyl-4-phenyl-4-propionoxypiperidine (9661) ...... I Tilidine (9750) ...... I Para-Fluorofentanyl (9812) ...... I 3-Methylfentanyl (9813) ...... I Alpha-Methylfentanyl (9814) ...... I Acetyl--methylfentanyl (9815) ...... I Beta-hydroxyfentanyl (9830) ...... I Beta-hydroxy-3-methylfentanyl (9831) ...... I Alpha-methylthiofentanyl (9832) ...... I 3-Methylthiofentanyl (9833) ...... I Thiofentanyl (9835) ...... I (1100) ...... II (1105) ...... II Lisdexamfetamine (1205) ...... II Phenmetrazine (1631) ...... II (1724) ...... II Amobarbital (2125) ...... II Pentobarbital (2270) ...... II Secobarbital (2315) ...... II Glutethimide (2550) ...... II (7379) ...... II 1-Phenylcyclohexylamine (7460) ...... II (7471) ...... II 1-Piperidinocyclohexanecarbonitrile (8603) ...... II Alphaprodine (9010) ...... II (9041) ...... II Codeine (9050) ...... II Dihydrocodeine (9120) ...... II Oxycodone (9143) ...... II Hydromorphone (9150) ...... II Diphenoxylate (9170) ...... II Benzoylecgonine (9180) ...... II Ethylmorphine (9190) ...... II Hydrocodone (9193) ...... II (9210) ...... II (9220) ...... II Isomethadone (9226) ...... II Meperidine (9230) ...... II Meperidine intermediate-A (9232) ...... II Meperidine intermediate-B (9233) ...... II Meperidine intermediate-C (9234) ...... II (9240) ...... II Methadone (9250) ...... II Methadone intermediate (9254) ...... II

VerDate Mar<15>2010 18:39 Jan 24, 2013 Jkt 229001 PO 00000 Frm 00096 Fmt 4703 Sfmt 4703 E:\FR\FM\25JAN1.SGM 25JAN1 mstockstill on DSK4VPTVN1PROD with Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices 5503

Drug Schedule

Dextropropoxyphene, bulk (non-dosage forms) (9273) ...... II Morphine (9300) ...... II Thebaine (9333) ...... II Levo-alphacetylmethadol (9648) ...... II Oxymorphone (9652) ...... II Noroxymorphone (9668) ...... II Racemethorphan (9732) ...... II Alfentanil (9737) ...... II Remifentanil (9739) ...... II Sufentanil (9740) ...... II Carfentanil (9743) ...... II Tapentadol (9780) ...... II Fentanyl (9801) ...... II

The company plans to manufacture manufacturer of Gamma Hydroxybutyric DEPARTMENT OF LABOR small quantities of the listed controlled Acid (2010), a basic class of controlled substances to make reference standards substance listed in schedule I. Office of the Secretary which will be distributed to their The company plans to manufacture customers. Agency Information Collection No comments or objections have been the listed controlled substance for Activities; Submission for OMB received. DEA has considered the distribution to its customers. Review; Comment Request; Statement factors in 21 U.S.C. 823(a) and No comments or objections have been of Expenditures and Financial determined that the registration of received. DEA has considered the Adjustment of Federal Funds for Cerilliant Corporation to manufacture factors in 21 U.S.C. 823(a), and Unemployment Compensation for the listed basic classes of controlled determined that the registration of Federal Employees and Ex- substances is consistent with the public Morton Grove Pharmaceuticals to Servicemembers interest at this time. DEA has manufacture the listed basic class of ACTION: investigated Cerilliant Corporation to controlled substance is consistent with Notice. ensure that the company’s registration is the public interest at this time. DEA has SUMMARY: The Department of Labor consistent with the public interest. The investigated Morton Grove investigation has included inspection (DOL) is submitting the Employment Pharmaceuticals to ensure that the and Training Administration (ETA) and testing of the company’s physical company’s registration is consistent security systems; verification of the sponsored information collection with the public interest. The company’s compliance with state and request (ICR) titled, ‘‘Statement of local laws; and a review of the investigation has included inspection Expenditures and Financial Adjustment company’s background and history. and testing of the company’s physical of Federal Funds for Unemployment Therefore, pursuant to 21 U.S.C. 823(a), security systems; verification of the Compensation for Federal Employees and in accordance with 21 CFR 1301.33, company’s compliance with state and and Ex-Servicemembers,’’ (Reporting the above named company is granted local laws; and a review of the Form ETA–191) to the Office of registration as a bulk manufacturer of company’s background and history. Management and Budget (OMB) for the basic classes of controlled Therefore, pursuant to 21 U.S.C. review and approval for continued use substances listed. 823(a), and in accordance with 21 CFR in accordance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. Dated: January 15, 2013. 1301.33, the above named company is 3501 et seq.). Joseph T. Rannazzisi, granted registration as a bulk Deputy Assistant Administrator, Office of manufacturer of the basic class of DATES: Submit comments on or before Diversion Control, Drug Enforcement controlled substance listed. February 25, 2013. Administration. Dated: January 14, 2013. ADDRESSES: A copy of this ICR with [FR Doc. 2013–01533 Filed 1–24–13; 8:45 am] applicable supporting documentation; Joseph T. Rannazzisi, BILLING CODE 4410–09–P including a description of the likely Deputy Assistant Administrator, Office of respondents, proposed frequency of Diversion Control, Drug Enforcement response, and estimated total burden DEPARTMENT OF JUSTICE Administration. may be obtained from the RegInfo.gov [FR Doc. 2013–01592 Filed 1–24–13; 8:45 am] Web site, http://www.reginfo.gov/ Drug Enforcement Administration BILLING CODE 4410–09–P public/do/PRAMain, on the day Manufacturer of Controlled following publication of this notice or Substances, Notice of Registration; by contacting Michel Smyth by Morton Grove Pharmaceuticals telephone at 202–693–4129 (this is not a toll-free number) or sending an email By Notice dated September 25, 2012, to [email protected]. and published in the Federal Register Submit comments about this request on October 2, 2012, 77 FR 60144, to the Office of Information and Morton Grove Pharmaceuticals, 6451 Regulatory Affairs, Attn: OMB Desk Main Street, Morton Grove, Illinois Officer for DOL–ETA, Office of 60053–2633, made application by letter Management and Budget, Room 10235, to the Drug Enforcement Administration 725 17th Street NW., Washington, DC (DEA) to be registered as a bulk 20503, Fax: 202–395–6881 (this is not a

VerDate Mar<15>2010 18:39 Jan 24, 2013 Jkt 229001 PO 00000 Frm 00097 Fmt 4703 Sfmt 4703 E:\FR\FM\25JAN1.SGM 25JAN1 mstockstill on DSK4VPTVN1PROD with